Kelsey Goodwin
Stock Analyst at Piper Sandler
(4.92)
# 28
Out of 5,163 analysts
37
Total ratings
78.12%
Success rate
67.67%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kelsey Goodwin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ERAS Erasca | Maintains: Overweight | $11 → $18 | $13.62 | +32.16% | 3 | Mar 13, 2026 | |
| ACLX Arcellx | Downgrades: Neutral | $120 → $115 | $114.39 | +0.53% | 4 | Feb 26, 2026 | |
| RVMD Revolution Medicines | Maintains: Overweight | $75 → $120 | $94.86 | +26.50% | 2 | Feb 26, 2026 | |
| TNGX Tango Therapeutics | Maintains: Overweight | $11 → $14 | $17.30 | -19.08% | 2 | Jan 16, 2026 | |
| JANX Janux Therapeutics | Maintains: Overweight | $42 → $30 | $13.58 | +120.91% | 2 | Jan 16, 2026 | |
| CGON CG Oncology | Maintains: Overweight | $55 → $70 | $64.29 | +8.88% | 2 | Jan 16, 2026 | |
| BDTX Black Diamond Therapeutics | Maintains: Overweight | $9 → $8 | $2.12 | +277.36% | 2 | Jan 16, 2026 | |
| TARA Protara Therapeutics | Initiates: Overweight | $24 | $5.26 | +356.27% | 1 | Jan 7, 2026 | |
| ORIC ORIC Pharmaceuticals | Initiates: Overweight | $22 | $11.90 | +84.87% | 1 | Jan 7, 2026 | |
| DAWN Day One Biopharmaceuticals | Maintains: Overweight | $25 → $26 | $21.31 | +22.01% | 1 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $112 → $128 | $97.93 | +30.71% | 4 | Oct 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $21 | $16.12 | +30.27% | 1 | Aug 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $36 | $18.45 | +95.12% | 4 | Aug 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $36 | $19.19 | +87.60% | 1 | Aug 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | n/a | $2.34 | - | 3 | Mar 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $2.60 | +207.69% | 1 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.00 | - | 1 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $18.75 | - | 1 | Oct 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $3.96 | - | 1 | Oct 31, 2022 |
Erasca
Mar 13, 2026
Maintains: Overweight
Price Target: $11 → $18
Current: $13.62
Upside: +32.16%
Arcellx
Feb 26, 2026
Downgrades: Neutral
Price Target: $120 → $115
Current: $114.39
Upside: +0.53%
Revolution Medicines
Feb 26, 2026
Maintains: Overweight
Price Target: $75 → $120
Current: $94.86
Upside: +26.50%
Tango Therapeutics
Jan 16, 2026
Maintains: Overweight
Price Target: $11 → $14
Current: $17.30
Upside: -19.08%
Janux Therapeutics
Jan 16, 2026
Maintains: Overweight
Price Target: $42 → $30
Current: $13.58
Upside: +120.91%
CG Oncology
Jan 16, 2026
Maintains: Overweight
Price Target: $55 → $70
Current: $64.29
Upside: +8.88%
Black Diamond Therapeutics
Jan 16, 2026
Maintains: Overweight
Price Target: $9 → $8
Current: $2.12
Upside: +277.36%
Protara Therapeutics
Jan 7, 2026
Initiates: Overweight
Price Target: $24
Current: $5.26
Upside: +356.27%
ORIC Pharmaceuticals
Jan 7, 2026
Initiates: Overweight
Price Target: $22
Current: $11.90
Upside: +84.87%
Day One Biopharmaceuticals
Nov 5, 2025
Maintains: Overweight
Price Target: $25 → $26
Current: $21.31
Upside: +22.01%
Oct 27, 2025
Maintains: Overweight
Price Target: $112 → $128
Current: $97.93
Upside: +30.71%
Aug 19, 2025
Initiates: Neutral
Price Target: $21
Current: $16.12
Upside: +30.27%
Aug 19, 2025
Initiates: Overweight
Price Target: $36
Current: $18.45
Upside: +95.12%
Aug 19, 2025
Initiates: Overweight
Price Target: $36
Current: $19.19
Upside: +87.60%
Mar 28, 2025
Reiterates: Buy
Price Target: n/a
Current: $2.34
Upside: -
Oct 29, 2024
Initiates: Buy
Price Target: $8
Current: $2.60
Upside: +207.69%
Jul 31, 2024
Downgrades: Neutral
Price Target: n/a
Current: $3.00
Upside: -
Oct 31, 2022
Initiates: Neutral
Price Target: n/a
Current: $18.75
Upside: -
Oct 31, 2022
Initiates: Neutral
Price Target: n/a
Current: $3.96
Upside: -